The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo

Ho Ngoc Nguyen, Shiaw Pyng Wey, Jyuhn Huarng Juang, Kiran Sonaje, Yi Cheng Ho, Er-Tuan Chuang, Chia Wei Hsu, Tzu Chen Yen, Kun Ju Lin, Hsing Wen Sung

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Exendin-4 is a potent insulinotropic agent in diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. In this study, an orally available exendin-4 formulation, using an enteric-coated capsule containing pH-responsive NPs, was developed. Following oral administration of 123I-labeled-exendin-4 loaded NPs in rats, the biodistribution of the administered drug was investigated using a dual isotope dynamic SPECT/CT scanner. The results showed that the radioactivity of 123I-exendin-4 propagated from the esophagus, stomach, and small intestine and then was absorbed into the systemic circulation; with time progressing, 123I-exendin-4 was metabolized and excreted into the urinary bladder. In the in vivo dissolution study, it was found that the enteric-coated capsule remained intact while in the stomach; the capsule was completely dissolved in the proximal segment of the small intestine and the loaded contents were then released. Oral administration of the capsule containing exendin-4 loaded NPs showed a maximum plasma concentration at 5 h after treatment; the bioavailability, relative to its subcutaneous counterpart, was found to be 14.0 ± 1.8%. The absorbed exendin-4 could then stimulate the insulin secretion and provide a prolonged glucose-lowering effect. The aforementioned results suggest that the orally available exendin-4 formulation developed warrants further exploration as a potential therapy for diabetic patients.

Original languageEnglish
Pages (from-to)2673-2682
Number of pages10
JournalBiomaterials
Volume32
Issue number10
DOIs
Publication statusPublished - Apr 2011
Externally publishedYes

Fingerprint

Insulin
Nanoparticles
Glucose
Radioactivity
Medical problems
Isotopes
Capsules
Rats
Dissolution
Plasmas
Small Intestine
Oral Administration
Stomach
exenatide
Biological Availability
Esophagus
Urinary Bladder
Therapeutics
Injections
Pharmaceutical Preparations

Keywords

  • Biodistribution
  • Chitosan
  • Insulin secretion
  • Oral delivery
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. / Nguyen, Ho Ngoc; Wey, Shiaw Pyng; Juang, Jyuhn Huarng; Sonaje, Kiran; Ho, Yi Cheng; Chuang, Er-Tuan; Hsu, Chia Wei; Yen, Tzu Chen; Lin, Kun Ju; Sung, Hsing Wen.

In: Biomaterials, Vol. 32, No. 10, 04.2011, p. 2673-2682.

Research output: Contribution to journalArticle

Nguyen, Ho Ngoc ; Wey, Shiaw Pyng ; Juang, Jyuhn Huarng ; Sonaje, Kiran ; Ho, Yi Cheng ; Chuang, Er-Tuan ; Hsu, Chia Wei ; Yen, Tzu Chen ; Lin, Kun Ju ; Sung, Hsing Wen. / The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. In: Biomaterials. 2011 ; Vol. 32, No. 10. pp. 2673-2682.
@article{255345bf8c644463b9279f896b9a263c,
title = "The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo",
abstract = "Exendin-4 is a potent insulinotropic agent in diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. In this study, an orally available exendin-4 formulation, using an enteric-coated capsule containing pH-responsive NPs, was developed. Following oral administration of 123I-labeled-exendin-4 loaded NPs in rats, the biodistribution of the administered drug was investigated using a dual isotope dynamic SPECT/CT scanner. The results showed that the radioactivity of 123I-exendin-4 propagated from the esophagus, stomach, and small intestine and then was absorbed into the systemic circulation; with time progressing, 123I-exendin-4 was metabolized and excreted into the urinary bladder. In the in vivo dissolution study, it was found that the enteric-coated capsule remained intact while in the stomach; the capsule was completely dissolved in the proximal segment of the small intestine and the loaded contents were then released. Oral administration of the capsule containing exendin-4 loaded NPs showed a maximum plasma concentration at 5 h after treatment; the bioavailability, relative to its subcutaneous counterpart, was found to be 14.0 ± 1.8{\%}. The absorbed exendin-4 could then stimulate the insulin secretion and provide a prolonged glucose-lowering effect. The aforementioned results suggest that the orally available exendin-4 formulation developed warrants further exploration as a potential therapy for diabetic patients.",
keywords = "Biodistribution, Chitosan, Insulin secretion, Oral delivery, Pharmacodynamics, Pharmacokinetics",
author = "Nguyen, {Ho Ngoc} and Wey, {Shiaw Pyng} and Juang, {Jyuhn Huarng} and Kiran Sonaje and Ho, {Yi Cheng} and Er-Tuan Chuang and Hsu, {Chia Wei} and Yen, {Tzu Chen} and Lin, {Kun Ju} and Sung, {Hsing Wen}",
year = "2011",
month = "4",
doi = "10.1016/j.biomaterials.2010.12.044",
language = "English",
volume = "32",
pages = "2673--2682",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",
number = "10",

}

TY - JOUR

T1 - The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo

AU - Nguyen, Ho Ngoc

AU - Wey, Shiaw Pyng

AU - Juang, Jyuhn Huarng

AU - Sonaje, Kiran

AU - Ho, Yi Cheng

AU - Chuang, Er-Tuan

AU - Hsu, Chia Wei

AU - Yen, Tzu Chen

AU - Lin, Kun Ju

AU - Sung, Hsing Wen

PY - 2011/4

Y1 - 2011/4

N2 - Exendin-4 is a potent insulinotropic agent in diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. In this study, an orally available exendin-4 formulation, using an enteric-coated capsule containing pH-responsive NPs, was developed. Following oral administration of 123I-labeled-exendin-4 loaded NPs in rats, the biodistribution of the administered drug was investigated using a dual isotope dynamic SPECT/CT scanner. The results showed that the radioactivity of 123I-exendin-4 propagated from the esophagus, stomach, and small intestine and then was absorbed into the systemic circulation; with time progressing, 123I-exendin-4 was metabolized and excreted into the urinary bladder. In the in vivo dissolution study, it was found that the enteric-coated capsule remained intact while in the stomach; the capsule was completely dissolved in the proximal segment of the small intestine and the loaded contents were then released. Oral administration of the capsule containing exendin-4 loaded NPs showed a maximum plasma concentration at 5 h after treatment; the bioavailability, relative to its subcutaneous counterpart, was found to be 14.0 ± 1.8%. The absorbed exendin-4 could then stimulate the insulin secretion and provide a prolonged glucose-lowering effect. The aforementioned results suggest that the orally available exendin-4 formulation developed warrants further exploration as a potential therapy for diabetic patients.

AB - Exendin-4 is a potent insulinotropic agent in diabetes patients; however, its therapeutic utility is limited due to the frequent injections required. In this study, an orally available exendin-4 formulation, using an enteric-coated capsule containing pH-responsive NPs, was developed. Following oral administration of 123I-labeled-exendin-4 loaded NPs in rats, the biodistribution of the administered drug was investigated using a dual isotope dynamic SPECT/CT scanner. The results showed that the radioactivity of 123I-exendin-4 propagated from the esophagus, stomach, and small intestine and then was absorbed into the systemic circulation; with time progressing, 123I-exendin-4 was metabolized and excreted into the urinary bladder. In the in vivo dissolution study, it was found that the enteric-coated capsule remained intact while in the stomach; the capsule was completely dissolved in the proximal segment of the small intestine and the loaded contents were then released. Oral administration of the capsule containing exendin-4 loaded NPs showed a maximum plasma concentration at 5 h after treatment; the bioavailability, relative to its subcutaneous counterpart, was found to be 14.0 ± 1.8%. The absorbed exendin-4 could then stimulate the insulin secretion and provide a prolonged glucose-lowering effect. The aforementioned results suggest that the orally available exendin-4 formulation developed warrants further exploration as a potential therapy for diabetic patients.

KW - Biodistribution

KW - Chitosan

KW - Insulin secretion

KW - Oral delivery

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=79251593382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251593382&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2010.12.044

DO - 10.1016/j.biomaterials.2010.12.044

M3 - Article

C2 - 21256586

AN - SCOPUS:79251593382

VL - 32

SP - 2673

EP - 2682

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 10

ER -